CA3001005C - Acides p-ethoxynucleiques pour une formulation liposomale - Google Patents

Acides p-ethoxynucleiques pour une formulation liposomale

Info

Publication number
CA3001005C
CA3001005C CA3001005A CA3001005A CA3001005C CA 3001005 C CA3001005 C CA 3001005C CA 3001005 A CA3001005 A CA 3001005A CA 3001005 A CA3001005 A CA 3001005A CA 3001005 C CA3001005 C CA 3001005C
Authority
CA
Canada
Prior art keywords
composition
oligonucleotide
oligonucleotides
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3001005A
Other languages
English (en)
Other versions
CA3001005A1 (fr
Inventor
Peter Nielsen
Original Assignee
Bio Path Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Path Holdings Inc filed Critical Bio Path Holdings Inc
Priority claimed from PCT/US2016/057148 external-priority patent/WO2017066643A1/fr
Publication of CA3001005A1 publication Critical patent/CA3001005A1/fr
Application granted granted Critical
Publication of CA3001005C publication Critical patent/CA3001005C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des oligonucléotides thérapeutiques qui comprennent au moins une liaison p-éthoxy-squelette mais pas plus de 80 % de liaisons p-éthoxy-squelette. La présente invention concerne des systèmes d'administration améliorés pour des oligonucléotides thérapeutiques comprenant un liposome qui comprend des phospholipides neutres et un p-éthoxy-oligonucléotide qui est piégé dans le liposome.
CA3001005A 2015-10-14 2016-10-14 Acides p-ethoxynucleiques pour une formulation liposomale Active CA3001005C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241503P 2015-10-14 2015-10-14
US62/241,503 2015-10-14
PCT/US2016/057148 WO2017066643A1 (fr) 2015-10-14 2016-10-14 Acides p-éthoxynucléiques pour une formulation liposomale

Publications (2)

Publication Number Publication Date
CA3001005A1 CA3001005A1 (fr) 2017-04-20
CA3001005C true CA3001005C (fr) 2024-07-02

Family

ID=

Similar Documents

Publication Publication Date Title
US12097214B2 (en) P-ethoxy nucleic acids for liposomal formulation
US20210115451A1 (en) P-ethoxy nucleic acids for igf-1r inhibition
US12472199B2 (en) P-ethoxy nucleic acids for IGF-1R inhibition
US12319911B2 (en) P-ethoxy nucleic acids for STAT3 inhibition
US12234457B2 (en) P-ethoxy nucleic acids for BCL2 inhibition
CA3001005C (fr) Acides p-ethoxynucleiques pour une formulation liposomale
CA3058486C (fr) Acides nucleiques p-ethoxy destines a inhiber bcl2
BR112018007611B1 (pt) Composição compreendendo oligonucleotídeos, composição farmacêutica compreendendo a dita composição, método in vitro para entregar o dito oligonucleotídeo a uma célula e uso da dita composição farmacêutica